acsf solution Search Results


90
Alconox Inc standard recording solution acsf
Standard Recording Solution Acsf, supplied by Alconox Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acsf+solution/standard+recording+solution+acsf/pmc07875980__41467_2021_21291_MOESM1_ESM-479-4-9
Average 90 stars, based on 1 article reviews
standard recording solution acsf - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Durect Corporation acsf solution
Hippocampal infusion of AMPA <t>receptor-specific</t> <t>TAT-S845</t> peptide affects manic-like behaviors. Rats were implanted bilaterally with cannula systems for continuous delivery of TAT-S845 peptide, control peptide TAT-SCR, or vehicle <t>(aCSF)</t> control. A, Open-field test. Eight days after surgery, rats were run in activity boxes for 60 min sessions. Distances traveled were scored by an automated tracking system. No significant differences were detected between treatment groups and controls for the 60 min time blocks or any of the constituent 5 min time blocks (n = 6; F(2,1077) = 1.816; p = 0.1632, one-way ANOVA). B, Amphetamine-induced hyperactivity. Ten days after surgery, rats were run in activity boxes for 30 min immediately followed by an intraperitoneal injection of 1 mg/kg amphetamine and placed back in the activity boxes for another 30 min. Distances traveled were scored as in the open-field test. One-way ANOVA detected no significant baseline differences in distances traveled among the aCSF, TAT-SCR peptide, and the TAT-S845 peptide groups. Significant differences in distances traveled among the groups for the amphetamine challenge test were detected (n = 6; F(2,537) = 11.06; p < 0.0001, one-way ANOVA; aCSF vs TAT-S845 groups, **p < 0.01); TAT-SCR peptide vs TAT-S845 peptide groups, ***p < 0.001; aCSF vs TAT-SCR peptide groups, p > 0.05; Tukey's post hoc tests). Error bars indicate SE.
Acsf Solution, supplied by Durect Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acsf+solution/acsf+solution/pmc02763546-227-10-12
Average 90 stars, based on 1 article reviews
acsf solution - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Merck & Co acsf solution composition
Hippocampal infusion of AMPA <t>receptor-specific</t> <t>TAT-S845</t> peptide affects manic-like behaviors. Rats were implanted bilaterally with cannula systems for continuous delivery of TAT-S845 peptide, control peptide TAT-SCR, or vehicle <t>(aCSF)</t> control. A, Open-field test. Eight days after surgery, rats were run in activity boxes for 60 min sessions. Distances traveled were scored by an automated tracking system. No significant differences were detected between treatment groups and controls for the 60 min time blocks or any of the constituent 5 min time blocks (n = 6; F(2,1077) = 1.816; p = 0.1632, one-way ANOVA). B, Amphetamine-induced hyperactivity. Ten days after surgery, rats were run in activity boxes for 30 min immediately followed by an intraperitoneal injection of 1 mg/kg amphetamine and placed back in the activity boxes for another 30 min. Distances traveled were scored as in the open-field test. One-way ANOVA detected no significant baseline differences in distances traveled among the aCSF, TAT-SCR peptide, and the TAT-S845 peptide groups. Significant differences in distances traveled among the groups for the amphetamine challenge test were detected (n = 6; F(2,537) = 11.06; p < 0.0001, one-way ANOVA; aCSF vs TAT-S845 groups, **p < 0.01); TAT-SCR peptide vs TAT-S845 peptide groups, ***p < 0.001; aCSF vs TAT-SCR peptide groups, p > 0.05; Tukey's post hoc tests). Error bars indicate SE.
Acsf Solution Composition, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acsf+solution/acsf+solution+composition/pm39329148-233-1-7
Average 90 stars, based on 1 article reviews
acsf solution composition - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Warner Instruments acsf solution
Hippocampal infusion of AMPA <t>receptor-specific</t> <t>TAT-S845</t> peptide affects manic-like behaviors. Rats were implanted bilaterally with cannula systems for continuous delivery of TAT-S845 peptide, control peptide TAT-SCR, or vehicle <t>(aCSF)</t> control. A, Open-field test. Eight days after surgery, rats were run in activity boxes for 60 min sessions. Distances traveled were scored by an automated tracking system. No significant differences were detected between treatment groups and controls for the 60 min time blocks or any of the constituent 5 min time blocks (n = 6; F(2,1077) = 1.816; p = 0.1632, one-way ANOVA). B, Amphetamine-induced hyperactivity. Ten days after surgery, rats were run in activity boxes for 30 min immediately followed by an intraperitoneal injection of 1 mg/kg amphetamine and placed back in the activity boxes for another 30 min. Distances traveled were scored as in the open-field test. One-way ANOVA detected no significant baseline differences in distances traveled among the aCSF, TAT-SCR peptide, and the TAT-S845 peptide groups. Significant differences in distances traveled among the groups for the amphetamine challenge test were detected (n = 6; F(2,537) = 11.06; p < 0.0001, one-way ANOVA; aCSF vs TAT-S845 groups, **p < 0.01); TAT-SCR peptide vs TAT-S845 peptide groups, ***p < 0.001; aCSF vs TAT-SCR peptide groups, p > 0.05; Tukey's post hoc tests). Error bars indicate SE.
Acsf Solution, supplied by Warner Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acsf+solution/acsf+solution/us09533007-237-0-30
Average 90 stars, based on 1 article reviews
acsf solution - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Nacalai acsf chemical solution
Hippocampal infusion of AMPA <t>receptor-specific</t> <t>TAT-S845</t> peptide affects manic-like behaviors. Rats were implanted bilaterally with cannula systems for continuous delivery of TAT-S845 peptide, control peptide TAT-SCR, or vehicle <t>(aCSF)</t> control. A, Open-field test. Eight days after surgery, rats were run in activity boxes for 60 min sessions. Distances traveled were scored by an automated tracking system. No significant differences were detected between treatment groups and controls for the 60 min time blocks or any of the constituent 5 min time blocks (n = 6; F(2,1077) = 1.816; p = 0.1632, one-way ANOVA). B, Amphetamine-induced hyperactivity. Ten days after surgery, rats were run in activity boxes for 30 min immediately followed by an intraperitoneal injection of 1 mg/kg amphetamine and placed back in the activity boxes for another 30 min. Distances traveled were scored as in the open-field test. One-way ANOVA detected no significant baseline differences in distances traveled among the aCSF, TAT-SCR peptide, and the TAT-S845 peptide groups. Significant differences in distances traveled among the groups for the amphetamine challenge test were detected (n = 6; F(2,537) = 11.06; p < 0.0001, one-way ANOVA; aCSF vs TAT-S845 groups, **p < 0.01); TAT-SCR peptide vs TAT-S845 peptide groups, ***p < 0.001; aCSF vs TAT-SCR peptide groups, p > 0.05; Tukey's post hoc tests). Error bars indicate SE.
Acsf Chemical Solution, supplied by Nacalai, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acsf+solution/acsf+chemical+solution/pmc04791292-50-36-41
Average 90 stars, based on 1 article reviews
acsf chemical solution - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Instech Laboratories 1× cm/acsf solution
Hippocampal infusion of AMPA <t>receptor-specific</t> <t>TAT-S845</t> peptide affects manic-like behaviors. Rats were implanted bilaterally with cannula systems for continuous delivery of TAT-S845 peptide, control peptide TAT-SCR, or vehicle <t>(aCSF)</t> control. A, Open-field test. Eight days after surgery, rats were run in activity boxes for 60 min sessions. Distances traveled were scored by an automated tracking system. No significant differences were detected between treatment groups and controls for the 60 min time blocks or any of the constituent 5 min time blocks (n = 6; F(2,1077) = 1.816; p = 0.1632, one-way ANOVA). B, Amphetamine-induced hyperactivity. Ten days after surgery, rats were run in activity boxes for 30 min immediately followed by an intraperitoneal injection of 1 mg/kg amphetamine and placed back in the activity boxes for another 30 min. Distances traveled were scored as in the open-field test. One-way ANOVA detected no significant baseline differences in distances traveled among the aCSF, TAT-SCR peptide, and the TAT-S845 peptide groups. Significant differences in distances traveled among the groups for the amphetamine challenge test were detected (n = 6; F(2,537) = 11.06; p < 0.0001, one-way ANOVA; aCSF vs TAT-S845 groups, **p < 0.01); TAT-SCR peptide vs TAT-S845 peptide groups, ***p < 0.001; aCSF vs TAT-SCR peptide groups, p > 0.05; Tukey's post hoc tests). Error bars indicate SE.
1× Cm/Acsf Solution, supplied by Instech Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acsf+solution/1%C3%97+cm+acsf+solution/pmc01779683-90-2-12
Average 90 stars, based on 1 article reviews
1× cm/acsf solution - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Burlington Industries artificial cerebrospinal fluid (acsf) solution
Hippocampal infusion of AMPA <t>receptor-specific</t> <t>TAT-S845</t> peptide affects manic-like behaviors. Rats were implanted bilaterally with cannula systems for continuous delivery of TAT-S845 peptide, control peptide TAT-SCR, or vehicle <t>(aCSF)</t> control. A, Open-field test. Eight days after surgery, rats were run in activity boxes for 60 min sessions. Distances traveled were scored by an automated tracking system. No significant differences were detected between treatment groups and controls for the 60 min time blocks or any of the constituent 5 min time blocks (n = 6; F(2,1077) = 1.816; p = 0.1632, one-way ANOVA). B, Amphetamine-induced hyperactivity. Ten days after surgery, rats were run in activity boxes for 30 min immediately followed by an intraperitoneal injection of 1 mg/kg amphetamine and placed back in the activity boxes for another 30 min. Distances traveled were scored as in the open-field test. One-way ANOVA detected no significant baseline differences in distances traveled among the aCSF, TAT-SCR peptide, and the TAT-S845 peptide groups. Significant differences in distances traveled among the groups for the amphetamine challenge test were detected (n = 6; F(2,537) = 11.06; p < 0.0001, one-way ANOVA; aCSF vs TAT-S845 groups, **p < 0.01); TAT-SCR peptide vs TAT-S845 peptide groups, ***p < 0.001; aCSF vs TAT-SCR peptide groups, p > 0.05; Tukey's post hoc tests). Error bars indicate SE.
Artificial Cerebrospinal Fluid (Acsf) Solution, supplied by Burlington Industries, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acsf+solution/artificial+cerebrospinal+fluid++acsf++solution/pmc09345760-86-15-44
Average 90 stars, based on 1 article reviews
artificial cerebrospinal fluid (acsf) solution - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Campden Instruments acsf solution
Hippocampal infusion of AMPA <t>receptor-specific</t> <t>TAT-S845</t> peptide affects manic-like behaviors. Rats were implanted bilaterally with cannula systems for continuous delivery of TAT-S845 peptide, control peptide TAT-SCR, or vehicle <t>(aCSF)</t> control. A, Open-field test. Eight days after surgery, rats were run in activity boxes for 60 min sessions. Distances traveled were scored by an automated tracking system. No significant differences were detected between treatment groups and controls for the 60 min time blocks or any of the constituent 5 min time blocks (n = 6; F(2,1077) = 1.816; p = 0.1632, one-way ANOVA). B, Amphetamine-induced hyperactivity. Ten days after surgery, rats were run in activity boxes for 30 min immediately followed by an intraperitoneal injection of 1 mg/kg amphetamine and placed back in the activity boxes for another 30 min. Distances traveled were scored as in the open-field test. One-way ANOVA detected no significant baseline differences in distances traveled among the aCSF, TAT-SCR peptide, and the TAT-S845 peptide groups. Significant differences in distances traveled among the groups for the amphetamine challenge test were detected (n = 6; F(2,537) = 11.06; p < 0.0001, one-way ANOVA; aCSF vs TAT-S845 groups, **p < 0.01); TAT-SCR peptide vs TAT-S845 peptide groups, ***p < 0.001; aCSF vs TAT-SCR peptide groups, p > 0.05; Tukey's post hoc tests). Error bars indicate SE.
Acsf Solution, supplied by Campden Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acsf+solution/acsf+solution/pmc06387506-55-10-17
Average 90 stars, based on 1 article reviews
acsf solution - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
ALA Scientific Instruments acsf solutions
Hippocampal infusion of AMPA <t>receptor-specific</t> <t>TAT-S845</t> peptide affects manic-like behaviors. Rats were implanted bilaterally with cannula systems for continuous delivery of TAT-S845 peptide, control peptide TAT-SCR, or vehicle <t>(aCSF)</t> control. A, Open-field test. Eight days after surgery, rats were run in activity boxes for 60 min sessions. Distances traveled were scored by an automated tracking system. No significant differences were detected between treatment groups and controls for the 60 min time blocks or any of the constituent 5 min time blocks (n = 6; F(2,1077) = 1.816; p = 0.1632, one-way ANOVA). B, Amphetamine-induced hyperactivity. Ten days after surgery, rats were run in activity boxes for 30 min immediately followed by an intraperitoneal injection of 1 mg/kg amphetamine and placed back in the activity boxes for another 30 min. Distances traveled were scored as in the open-field test. One-way ANOVA detected no significant baseline differences in distances traveled among the aCSF, TAT-SCR peptide, and the TAT-S845 peptide groups. Significant differences in distances traveled among the groups for the amphetamine challenge test were detected (n = 6; F(2,537) = 11.06; p < 0.0001, one-way ANOVA; aCSF vs TAT-S845 groups, **p < 0.01); TAT-SCR peptide vs TAT-S845 peptide groups, ***p < 0.001; aCSF vs TAT-SCR peptide groups, p > 0.05; Tukey's post hoc tests). Error bars indicate SE.
Acsf Solutions, supplied by ALA Scientific Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acsf+solution/acsf+solutions/pmc03032005-123-2-21
Average 90 stars, based on 1 article reviews
acsf solutions - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Fisher Scientific all chemicals for making the sucrose acsf, acsf, and intracellular electrolyte solution
Hippocampal infusion of AMPA <t>receptor-specific</t> <t>TAT-S845</t> peptide affects manic-like behaviors. Rats were implanted bilaterally with cannula systems for continuous delivery of TAT-S845 peptide, control peptide TAT-SCR, or vehicle <t>(aCSF)</t> control. A, Open-field test. Eight days after surgery, rats were run in activity boxes for 60 min sessions. Distances traveled were scored by an automated tracking system. No significant differences were detected between treatment groups and controls for the 60 min time blocks or any of the constituent 5 min time blocks (n = 6; F(2,1077) = 1.816; p = 0.1632, one-way ANOVA). B, Amphetamine-induced hyperactivity. Ten days after surgery, rats were run in activity boxes for 30 min immediately followed by an intraperitoneal injection of 1 mg/kg amphetamine and placed back in the activity boxes for another 30 min. Distances traveled were scored as in the open-field test. One-way ANOVA detected no significant baseline differences in distances traveled among the aCSF, TAT-SCR peptide, and the TAT-S845 peptide groups. Significant differences in distances traveled among the groups for the amphetamine challenge test were detected (n = 6; F(2,537) = 11.06; p < 0.0001, one-way ANOVA; aCSF vs TAT-S845 groups, **p < 0.01); TAT-SCR peptide vs TAT-S845 peptide groups, ***p < 0.001; aCSF vs TAT-SCR peptide groups, p > 0.05; Tukey's post hoc tests). Error bars indicate SE.
All Chemicals For Making The Sucrose Acsf, Acsf, And Intracellular Electrolyte Solution, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acsf+solution/all+chemicals+for+making+the+sucrose+acsf++acsf++and+intracellular+electrolyte+solution/pmc03547472-269-8-15
Average 90 stars, based on 1 article reviews
all chemicals for making the sucrose acsf, acsf, and intracellular electrolyte solution - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Avantor acsf solutions
Hippocampal infusion of AMPA <t>receptor-specific</t> <t>TAT-S845</t> peptide affects manic-like behaviors. Rats were implanted bilaterally with cannula systems for continuous delivery of TAT-S845 peptide, control peptide TAT-SCR, or vehicle <t>(aCSF)</t> control. A, Open-field test. Eight days after surgery, rats were run in activity boxes for 60 min sessions. Distances traveled were scored by an automated tracking system. No significant differences were detected between treatment groups and controls for the 60 min time blocks or any of the constituent 5 min time blocks (n = 6; F(2,1077) = 1.816; p = 0.1632, one-way ANOVA). B, Amphetamine-induced hyperactivity. Ten days after surgery, rats were run in activity boxes for 30 min immediately followed by an intraperitoneal injection of 1 mg/kg amphetamine and placed back in the activity boxes for another 30 min. Distances traveled were scored as in the open-field test. One-way ANOVA detected no significant baseline differences in distances traveled among the aCSF, TAT-SCR peptide, and the TAT-S845 peptide groups. Significant differences in distances traveled among the groups for the amphetamine challenge test were detected (n = 6; F(2,537) = 11.06; p < 0.0001, one-way ANOVA; aCSF vs TAT-S845 groups, **p < 0.01); TAT-SCR peptide vs TAT-S845 peptide groups, ***p < 0.001; aCSF vs TAT-SCR peptide groups, p > 0.05; Tukey's post hoc tests). Error bars indicate SE.
Acsf Solutions, supplied by Avantor, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acsf+solution/acsf+solutions/pmc04776517-382-5-10
Average 90 stars, based on 1 article reviews
acsf solutions - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Fisher Scientific compounds for acsf and pipette solution
Hippocampal infusion of AMPA <t>receptor-specific</t> <t>TAT-S845</t> peptide affects manic-like behaviors. Rats were implanted bilaterally with cannula systems for continuous delivery of TAT-S845 peptide, control peptide TAT-SCR, or vehicle <t>(aCSF)</t> control. A, Open-field test. Eight days after surgery, rats were run in activity boxes for 60 min sessions. Distances traveled were scored by an automated tracking system. No significant differences were detected between treatment groups and controls for the 60 min time blocks or any of the constituent 5 min time blocks (n = 6; F(2,1077) = 1.816; p = 0.1632, one-way ANOVA). B, Amphetamine-induced hyperactivity. Ten days after surgery, rats were run in activity boxes for 30 min immediately followed by an intraperitoneal injection of 1 mg/kg amphetamine and placed back in the activity boxes for another 30 min. Distances traveled were scored as in the open-field test. One-way ANOVA detected no significant baseline differences in distances traveled among the aCSF, TAT-SCR peptide, and the TAT-S845 peptide groups. Significant differences in distances traveled among the groups for the amphetamine challenge test were detected (n = 6; F(2,537) = 11.06; p < 0.0001, one-way ANOVA; aCSF vs TAT-S845 groups, **p < 0.01); TAT-SCR peptide vs TAT-S845 peptide groups, ***p < 0.001; aCSF vs TAT-SCR peptide groups, p > 0.05; Tukey's post hoc tests). Error bars indicate SE.
Compounds For Acsf And Pipette Solution, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acsf+solution/compounds+for+acsf+and+pipette+solution/pm24244421-78-6-11
Average 90 stars, based on 1 article reviews
compounds for acsf and pipette solution - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Hippocampal infusion of AMPA receptor-specific TAT-S845 peptide affects manic-like behaviors. Rats were implanted bilaterally with cannula systems for continuous delivery of TAT-S845 peptide, control peptide TAT-SCR, or vehicle (aCSF) control. A, Open-field test. Eight days after surgery, rats were run in activity boxes for 60 min sessions. Distances traveled were scored by an automated tracking system. No significant differences were detected between treatment groups and controls for the 60 min time blocks or any of the constituent 5 min time blocks (n = 6; F(2,1077) = 1.816; p = 0.1632, one-way ANOVA). B, Amphetamine-induced hyperactivity. Ten days after surgery, rats were run in activity boxes for 30 min immediately followed by an intraperitoneal injection of 1 mg/kg amphetamine and placed back in the activity boxes for another 30 min. Distances traveled were scored as in the open-field test. One-way ANOVA detected no significant baseline differences in distances traveled among the aCSF, TAT-SCR peptide, and the TAT-S845 peptide groups. Significant differences in distances traveled among the groups for the amphetamine challenge test were detected (n = 6; F(2,537) = 11.06; p < 0.0001, one-way ANOVA; aCSF vs TAT-S845 groups, **p < 0.01); TAT-SCR peptide vs TAT-S845 peptide groups, ***p < 0.001; aCSF vs TAT-SCR peptide groups, p > 0.05; Tukey's post hoc tests). Error bars indicate SE.

Journal:

Article Title: The Role of Hippocampal GluR1 and GluR2 Receptors in Manic-Like Behavior

doi: 10.1523/JNEUROSCI.3080-07.2008

Figure Lengend Snippet: Hippocampal infusion of AMPA receptor-specific TAT-S845 peptide affects manic-like behaviors. Rats were implanted bilaterally with cannula systems for continuous delivery of TAT-S845 peptide, control peptide TAT-SCR, or vehicle (aCSF) control. A, Open-field test. Eight days after surgery, rats were run in activity boxes for 60 min sessions. Distances traveled were scored by an automated tracking system. No significant differences were detected between treatment groups and controls for the 60 min time blocks or any of the constituent 5 min time blocks (n = 6; F(2,1077) = 1.816; p = 0.1632, one-way ANOVA). B, Amphetamine-induced hyperactivity. Ten days after surgery, rats were run in activity boxes for 30 min immediately followed by an intraperitoneal injection of 1 mg/kg amphetamine and placed back in the activity boxes for another 30 min. Distances traveled were scored as in the open-field test. One-way ANOVA detected no significant baseline differences in distances traveled among the aCSF, TAT-SCR peptide, and the TAT-S845 peptide groups. Significant differences in distances traveled among the groups for the amphetamine challenge test were detected (n = 6; F(2,537) = 11.06; p < 0.0001, one-way ANOVA; aCSF vs TAT-S845 groups, **p < 0.01); TAT-SCR peptide vs TAT-S845 peptide groups, ***p < 0.001; aCSF vs TAT-SCR peptide groups, p > 0.05; Tukey's post hoc tests). Error bars indicate SE.

Article Snippet: Peptides TAT-S845 and TAT-SCR control peptides were dissolved in an aCSF solution (Alzet, Cupertino, CA) at a concentration of 160 μ m . 4-(8-Methyl-9 H -1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-benzenamine hydrochloride (GYKI 52466; 50 μ m ), a selective AMPA receptor antagonist, was obtained from Tocris (Ellisville, MO).

Techniques: Activity Assay, Injection